RxDoctor Payments Data

Marlon Ramilo, MD

Cardiovascular Disease · Modesto, CANPI 1659316412

Payments from drug & device makers

$496,298in general payments, 2019–2025

Across 1,037 payments — averaging $478.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$208K
  • Merck$149K
  • Johnson & Johnson$91K
  • Bayer$17K
  • Novartis$9K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$8K
  • plus $16K from 30 others

What the payments were for

  • Consulting fees$7750%
  • Speaking & faculty fees$386,93878%
  • Travel & lodging$78,66816%
  • Food & beverage$29,6186%
  • Education$2980%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$496,298 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$363,004
Medicare patients
1,138
Services billed
4,902

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AdempasRiociguat55$773,262
Tyvaso DpiTreprostinil21$538,283
XareltoRivaroxaban288$306,970
UptraviSelexipag11$256,509
VerquvoVericiguat135$172,987
LetairisAmbrisentan13$169,121
OpsumitMacitentan13$162,163
OzempicSemaglutide89$128,611
EntrestoSacubitril/Valsartan97$119,879
EliquisApixaban108$118,142
JardianceEmpagliflozin98$113,132
Repatha SureclickEvolocumab138$103,717
RybelsusSemaglutide54$67,189
FarxigaDapagliflozin Propanediol40$45,703
BrilintaTicagrelor40$29,873

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerAdempas$17,146$773,26255 claims
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit$484$418,67224 claims
Johnson & JohnsonXarelto$91,125$306,970288 claims
Novo NordiskOzempic, Rybelsus, Wegovy$207,653$209,917154 claims
MerckVerquvo$148,516$172,987135 claims
GileadLetairis$48$169,12113 claims
NovartisEntresto$8,590$119,87997 claims
PfizerEliquis$66$118,142108 claims
Boehringer IngelheimJardiance$546$113,13298 claims
AstraZenecaFarxiga, Brilinta$655$75,57680 claims
Esperion Therapeutics, Inc.Nexlizet$331$17,46415 claims
Lilly USA, LLCTrulicity$335$9,95212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Modesto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →